updat model iqvia follow earn releas wednesday
quarter result expect top bottom line book
slightli expect quarterli book-to-bil vs estim
net award year-ago level manag commentari
organ growth commerci solut also
reassur yet indic compani definit take share
legaci cro busi improv transpar report
increas revenu estim million billion
total organ constant currenc maintain ep estim
though suspect underli organ growth commerci solut
 segment remain around remaind year believ
solid book past year allow organ growth pick
beyond expect manag on-going focu cost cut capit
deploymentvia share repurchasesshould lead bottom-lin growth
midteen next year maintain outperform rate view
current valuat attract
exhibit iqvia organ growth present
return equiti ttm
iqvia integr inform technology-en healthcar servic provid annual revenu base
approach billion form merger quintil im health compani employ
roughli employe oper countri compani world lead provid
pharmaceut sale prescript data leader outsourc drug develop commerci
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
segment observ expect
commerci solut increas organ constant-curr basi quarter remaind
year expect roughli organ growth acquisit benefit declin back half
year aggreg estim report growth segment previous
 increas organ constant-curr basi quarter remaind
year expect organ growth hold steadi level compani book-to-bil ratio
quarter ratio year-over-year backlog growth
methodolog quarter give us addit comfort organ growth busi gradual
improv compar current level howev expect take time lower
award still impact top-lin growth model consist growth
solut segment growth pick previous model organ growth
expect growth ramp throughout year result adjust organ
growth target segment next-gen offer appear gain momentum
intrigu commentari greater invest function contract virtual trial
appear rfp environ also tick first quarter consist respons recent survey
posit demand commentari competitor health outperform medpac
integr decreas constant currenc basi first quarter expect
similar declin remaind though expect new region sale model lessen
rate declin beyond continu model declin next two year
make adjust second quarter estim reflect manag guidanc increas
revenu target million billion though decreas ep estim
result higher expect invest
full year increas revenu target million billion maintain ep
estim
increas revenu estim million billion maintain ep estim
valuat stock thought
follow wednesday declin trade time unchang estim valuat
nearli turn discount cro group time turn stock five-year averag time
maintain outperform rate time given continu solid book trend path improv
organ growth beyond updat model iqvia follow
exhibit updat iqvia hold incom statement summari
profit gener administr expens amort incom includ option beg incom expens tax investe non-controlling interests/minor hedg incom tax non control item net incom excl non-recurring item incl option beg averag share outstand averag share outstand analysi gross rate revenu begin excl foreign exchang effect pro forma beg organ pro forma beg incom excl non-recur excl non-recur item incl blair compani estimatesourc compani report william blair compani llc estim import disclosur
